Protagonist Therapeutics Inc (PTGX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Protagonist Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Protagonist Therapeutics Inc (PTGX) has returned 20.68% so far this year and 117.95% over the past 12 months.

Based on dividend-adjusted daily data since Aug 11, 2016, PTGX's average daily return is +0.25%, while the average monthly return is +4.81%. At this rate, your investment would double in approximately 1.2 years.

Historically, 55% of months were positive and 45% were negative. The best month was May 2020 with a return of +144.9%, while the worst month was Sep 2021 at -63.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, PTGX closed higher 50% of trading days. The best single day was Oct 11, 2021 with a return of +93.9%, while the worst single day was Sep 17, 2021 at -62.0%.

Protagonist Therapeutics Inc has an annualized alpha of 65.63%, beta of 1.01, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since August 12, 2016.

• This stock captured 240.87% of S&P 500 Index gains and 157.66% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PTGX ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Protagonist Therapeutics Inc (PTGX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Protagonist Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Protagonist Therapeutics Inc was 85.79%, occurring on Jun 13, 2022. Recovery took 686 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Protagonist Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Protagonist Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.